Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC.

An improved separation of the human serum N-glycome using hydrophilic interaction chromatography technology with UPLC is described, where more than 140 N-glycans were assigned. Using this technique, serum samples from 107 healthy controls and 62 newly diagnosed breast cancer patients were profiled. The most statistically significant alterations were observed in cancer patients compared with healthy controls: an increase in sialylation, branching, and outer-arm fucosylation and a decrease in high-mannosylated and biantennary core-fucosylated glycans. In the controls and cases combined systemic features were analyzed; serum estradiol was associated with increase in digalactosylated glycans, and higher mammographic density was associated with increase in biantennary digalactosylated glycans and with decrease in trisialylated and in outer-arm fucosylated glycans. Furthermore, particular glycans were altered in some features of the breast carcinomas; bisected biantennary nonfucosylated glycans were decreased in patients with progesterone receptor positive tumors, and core-fucosylated biantennary bisected monogalactosylated glycans were decreased in patients with the TP53 mutation. Systemic features show more significant associations with the serum N-glycome than do the features of the breast carcinomas. In conclusion, the UPLC-based glycan analysis technique described here reveals highly significant differences between healthy women and breast cancer patients. Significant associations with breast carcinoma and systemic features are described.

[1]  R. Dwek,et al.  Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. , 1997, Analytical biochemistry.

[2]  A. Leathem,et al.  Lectin microarray profiling of metastatic breast cancers. , 2011, Glycobiology.

[3]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[4]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[5]  Torben Lüders,et al.  Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density , 2010, Breast Cancer Research.

[6]  Niclas G Karlsson,et al.  Negative ion graphitised carbon nano-liquid chromatography/mass spectrometry increases sensitivity for glycoprotein oligosaccharide analysis. , 2004, Rapid communications in mass spectrometry : RCM.

[7]  Mary Ann Comunale,et al.  Increased Levels of Tetra-antennary N-Linked Glycan but Not Core Fucosylation Are Associated with Hepatocellular Carcinoma Tissue , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[8]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N F Boyd,et al.  Mammographic densities and breast cancer risk. , 1998, Breast disease.

[10]  David J. Harvey,et al.  HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. , 2008, Analytical biochemistry.

[11]  Kit S. Lam,et al.  A Serum Glycomics Approach to Breast Cancer Biomarkers*S , 2007, Molecular & Cellular Proteomics.

[12]  F. Clavel-Chapelon,et al.  Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC) , 2004, International journal of cancer.

[13]  V. Reinhold,et al.  The N-glycome of human plasma. , 2010, Journal of proteome research.

[14]  Guy N Brock,et al.  Interrogating differences in expression of targeted gene sets to predict breast cancer outcome , 2013, BMC Cancer.

[15]  D. Walerych,et al.  The rebel angel: mutant p53 as the driving oncogene in breast cancer , 2012, Carcinogenesis.

[16]  Jacob J. Kennedy,et al.  The development of an integrated platform to identify breast cancer glycoproteome changes in human serum. , 2010, Journal of chromatography. A.

[17]  A. Børresen-Dale,et al.  Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas , 2011, BMC Cancer.

[18]  I. Vejborg,et al.  Breast density and outcome of mammography screening: a cohort study , 2009, British Journal of Cancer.

[19]  William C Hines,et al.  Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.

[20]  Pauline M Rudd,et al.  Detailed structural analysis of N-glycans released from glycoproteins in SDS-PAGE gel bands using HPLC combined with exoglycosidase array digestions. , 2006, Methods in molecular biology.

[21]  Yehia Mechref,et al.  Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. , 2008, Clinical chemistry.

[22]  Karla Kerlikowske,et al.  Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. , 2012, Journal of the National Cancer Institute.

[23]  R. Dwek,et al.  Changes of serum glycans during sepsis and acute pancreatitis. , 2007, Glycobiology.

[24]  J. Schneider,et al.  Circulating hormone levels in breast cancer patients. correlation with serum tumor markers and the clinical and biological features of the tumors. , 2005, Anticancer research.

[25]  M. Pierobon,et al.  Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis , 2012, Breast Cancer Research and Treatment.

[26]  I. Rudan,et al.  Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. , 2010, Glycobiology.

[27]  M Brunet,et al.  Relationship of presence of progesterone receptors to prognosis in early breast cancer. , 1980, Cancer research.

[28]  M. Fang,et al.  The Identification and Characterization of Novel N-glycan-based Biomarkers in Gastric Cancer , 2013, PloS one.

[29]  D. Rose,et al.  Interaction between menopausal status and obesity in affecting breast cancer risk. , 2010, Maturitas.

[30]  T. Sørlie,et al.  Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression , 2010, Molecular oncology.

[31]  S. Cummings,et al.  Elevated Serum Estradiol and Testosterone Concentrations Are Associated with a High Risk for Breast Cancer , 1999, Annals of Internal Medicine.

[32]  Pauline M Rudd,et al.  Automated, high-throughput IgG-antibody glycoprofiling platform. , 2013, Analytical chemistry.

[33]  Pauline M Rudd,et al.  A systematic approach to protein glycosylation analysis: a path through the maze. , 2010, Nature chemical biology.

[34]  T. Nakagawa,et al.  Biological function of fucosylation in cancer biology. , 2007, Journal of biochemistry.

[35]  J R Marshall,et al.  Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. , 2000, American journal of epidemiology.

[36]  Joseph Zaia,et al.  Mass spectrometry and glycomics. , 2010, Omics : a journal of integrative biology.

[37]  Nichollas E. Scott,et al.  Site-specific glycan-peptide analysis for determination of N-glycoproteome heterogeneity. , 2013, Journal of proteome research.

[38]  R. Parekh,et al.  Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. , 1995, Analytical biochemistry.